Study shows how glucocorticoid hormones control sugar and fat levels over the course of 24 hours
This new study, which included more than 4,200 postmenopausal women, is one of the few large-scale studies known to assess the link between use of HT and muscle loss in postmenopausal women. More specifically, it focused on the duration of HT use and its effect on muscle mass and the prevalence of sarcopenia.
On the basis of study results, which appear in the article "The association between hormone therapy and sarcopenia in postmenopausal women: the Korea National Health and Nutrition Examination Survey, 2008-2011," the researchers concluded that prolonged use of HT is associated with higher muscle mass and a lower prevalence of sarcopenia in postmenopausal women.
Although not all studies examining an association between hormone therapy and muscle mass have shown positive results, this large cross-sectional study demonstrated a relationship between extended use of hormone therapy and both greater muscle mass and lower risk of sarcopenia in women aged younger than 65 years and with a body mass index less than 25 kg/m 2 . The mechanism by which estrogen protects muscle mass remains unclear, and additional study is needed." Dr. Stephanie Faubion, NAMS medical director Source:
The North American Menopause Society (NAMS) Journal reference:
Sung-Woo, K., et al. (2020) The association between hormone therapy and sarcopenia in postmenopausal women, the Korea National Health and Nutrition Examination Survey, 2008-2011. Menopause . doi.org/10.1097/GME. 1509 .
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology